News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

May

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

30

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

AVISE® Lupus and AVISE® CTD tests included in agreement SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE)...

22

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

New partnership will bring total patients with in-network testing benefit to more than 90...

22

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin...

10

Exagen Inc. Reports Third Quarter 2021 Results

Quarterly Records: Ordering Healthcare Providers and Adopters SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq:...

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock

Offering 3.7 million shares of common stock at $16.25/share SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE)...

Recent developments

May

11

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

March

30

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

March

22

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

March

22

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

November

10

Exagen Inc. Reports Third Quarter 2021 Results

March

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock